Why UroGen Pharma Ltd.’s (URGN) Stock Is Down 5.17%
As of Friday, July 31, UroGen Pharma Ltd.’s URGN share price has dipped by 5.17%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Commentary & Analysis
Why UroGen Pharma Ltd.’s (URGN) Stock Is Up 5.64%
As of Thursday, June 04, UroGen Pharma Ltd.’s URGN share price has surged by 5.64%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why UroGen Pharma Ltd.’s (URGN) Stock Is Down 5.38%
As of Thursday, May 14, UroGen Pharma Ltd.’s URGN share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why UroGen Pharma Ltd.’s (URGN) Stock Is Up 6.31%
As of Monday, May 11, UroGen Pharma Ltd.’s URGN share price has surged by 6.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why UroGen Pharma Ltd.’s (URGN) Stock Is Up 13.13%
As of Friday, May 08, UroGen Pharma Ltd.’s URGN share price has surged by 13.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | URGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,861.2 | $252.6 | 53% |
|
| Shares Out (Mil) | 50.2 | 52.3 | 48% |
|
| Institutional Ownership | 97.8% | 92.1% | 76% |
|
| Float (Mil) | 43.2 | 40.2 | 44% |
|
| Beta | 1.59 | 0.95 | 84% |
|
| Avg Daily Volume (000s) | 592 | 455 | 62% |
|
| Price Change (52-week) |
98.8% | 52.9% | 91% |
|
| Growth | URGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.2% | 13.6% | 97% |
|
| Net Income (5yr) | (3.6%) | (9.9%) | 35% |
|
| EPS (5yr) | 11.6% | 16.0% | 49 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (55.4%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.265) | ($0.705) | $1.494 | |
| Month Ago EPS | ($0.304) | ($0.905) | $1.229 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.360) | ($1.088) | $1.171 | |
| Year/Year Chg | (43.6%) | (77.9%) | (211.3%) | |
| Financials | URGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $141 | $38 | 29% |
|
| Net Income (TTM) (Mil) | ($133) | ($43) | 9% |
|
| EPS (TTM) | ($2.730) | ($1.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($166) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $5 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $195 | $5 | 50% |
|
| Enterprise Value (Q1) (Mil) | $1,489 | $180 | 46% |
|
| Valuation | URGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | URGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 89.9% | 63.8% | 93% |
|
| Net Margin | (94.8%) | (67.3%) | 8% |
|
| ROA | (53.2%) | (49.8%) | 11% |
|
| ROE | 156.1% | (55.5%) | 97% |
|
| Liabilities to Assets | 149.0% | 30.3% | 98% |
|
| F-Score | 3 | 3 | 19% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.5% |
| +/- S&P 500: | +14.0 |
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 22.7% |
| +/- S&P 500: | +15.2 |
